Cyberounds Logo
August 11, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Intravenous Immunoglobulin Therapy in Rheumatological Disorders
CME credit is no longer available for this conference.
Mohammad Kamran, M.D., Bernard Hojaili, M.D., and Peter Barland, M.D.

Dr. Kamran and Dr. Hojaili are fellows in the Division of Rheumatology, Department of Medicine, the Albert Einstein College of Medicine and Montefiore Medical Center, New York.

Within the past 12 months, Dr. Kamran, Hojaili and Barland report no commercial conflicts of interest.

Release Date: 10/03/2006
Termination Date: 10/03/2009

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the possible mechanisms of action of IVIG as an immunomodulator
  • List rheumatological conditions where IVIG is of proven benefit
  • Discuss rheumatological conditions where IVIG is either only occasionally or questionably beneficial.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity